Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 267 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Some People with Rectal Cancer Can Skip Radiation Before Surgery July 19, 2023 Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... May 2, 2019 How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 EMA Recommends Granting a Marketing Authorisation for Catumaxomab November 12, 2024 Load more HOT NEWS Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities...
